Health Trials

Thrombocytopenia, Neonatal Alloimmune

2

Review clinical trials related to Thrombocytopenia, Neonatal Alloimmune. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

The purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Participants needed: 50
Trial details
Phase: Phase 3Age: 18-45Biological sex: FemaleType: InterventionalSponsor: Janssen Research & Development, LLCUpdated: Aug 28, 2026Locations: 28
Eligibility criteria

Pregnant and an estimated gestational age (GA) from week 13* to 18 at visit 1 [+4]

Currently pregnant with multiple gestations (twins or more) [+4]

Read more
Status: Recruiting

A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

The purpose of this study is to evaluate the effectiveness of nipocalimab compared with placebo in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Participants needed: 39
Trial details
Phase: Phase 3Age: 18-45Biological sex: FemaleType: InterventionalSponsor: Janssen Research & Development, LLCUpdated: Aug 28, 2026Locations: 21
Eligibility criteria

Pregnant and an estimated gestational age (GA; based on ultrasound dating) from... [+4]

Currently pregnant with multiple gestations (twins or more) [+4]

Read more